Navigation Links
Endo Pharmaceuticals Provides Regulatory Update on New Formulation of OPANA® ER Designed to be Crush-Resistant
Date:1/7/2011

CHADDS FORD, Pa., Jan. 7, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) today announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for its new formulation of OPANA® ER designed to be crush resistant.  The complete response letter did not require that additional clinical studies be conducted for approval of the NDA.

"As a result of ongoing discussions with FDA, we have begun to address the issue from the complete response letter and will work closely with the agency to finalize our response," said Dr. Ivan Gergel, M.D., executive vice president, R&D, Endo Pharmaceuticals. "We are confident that we can address the issue set forth, currently anticipate responding to the FDA by mid 2011 and would expect a six month review cycle once our response is filed.  We remain focused on bringing this new formulation of OPANA ER to market for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time."

About Endo

Endo Pharmaceuticals is a U.S.-based, specialty healthcare solutions company, focused on high-value branded products and specialty generics. Endo is redefining its position in the healthcare marketplace by anticipating and embracing the evolution of health decisions based on the need for high-quality and cost-effective care. We aim to be the premier partner to healthcare professionals and payment providers, delivering an innovative suite of complementary diagnostics, drugs, devices and clinical data to meet the needs of patients in areas such as pain, urology, oncology and endocrinology. For more information about Endo Pharmaceuticals, and its wholly owned subsidiaries HealthTronics, Inc. and Qualitest Pharmaceuticals, please visit w
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... /PRNewswire-iReach/ -- Dan York has been named ... the RTD ® Advanced Wound Care Dressing, as ... presence in the U.S. Under York,s leadership, GWM Products, ... sales representatives in new sales territories that will complement ... up to 20 sales representatives in major metropolitan areas ...
(Date:9/16/2014)... Sept. 16, 2014 Adaptive Biotechnologies, a clinical ... to profile the adaptive immune system, is pleased to ... Chief Commercial Officer (CCO). The addition of Brain to ... hires from leading global healthcare companies, including Dean ... Counsel) from Genomic Health and Sean Nolan ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 2Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011 Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... present at the Sixth Annual JMP Securities Healthcare Conference on ... a.m. Pacific Time) at The St. Regis New York Hotel ... Executive Officer, is scheduled to provide a corporate overview. ...
... MINNEAPOLIS, Sept. 21, 2011 Uroplasty, Inc. (NASDAQ: ... markets innovative proprietary products to treat voiding dysfunctions, announced today ... President and CFO, will present the Company,s business strategy and ... at 2:30 PM ET on Tuesday, September 27, 2011 at ...
Cached Medicine Technology:Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 2Arena Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference 3Uroplasty to Present at the 6th Annual JMP Securities Healthcare Conference 2
(Date:9/16/2014)... News) -- One in five American men admits ... a new survey shows. A nationally representative ... such violence is more prevalent than diabetes. This ... slapping and hitting, kicking, biting, choking, burning or ... said. Although abuse by high-profile professional athletes ...
(Date:9/16/2014)... School of Medicine researcher Dr. Jeffrey Samet and ... recently awarded a five year, $5 million grant ... their project titled: Improving Physician Opioid Prescribing for ... are the second most commonly abused substances in ... to prescription opioids now exceed deaths from motor ...
(Date:9/16/2014)... Since the adoption of pediatric legislation, ... in line with increased investment in R&D for pediatric ... novel paediatric information and more than 130 products have ... there has been 221 changes relating to the efficacy ... old or new trials in children and 89 additions ...
(Date:9/16/2014)... testing ground, researchers at Johns Hopkins have shown that ... can substantially reduce patient wait times and possibly improve ... report on the pilot study, published online Sept. 9, ... so-called "Just-in-Time" training and inventory process used now by ... keep complicated operations from bottlenecking. , "We realized that ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 RxAnte, ... predictive analytics and targeted clinical programs, today announced ... changes support the Company’s drive to improve medication ... targeted clinical programs. On September 2, 2014, Brock ... Millennium Health, announced that RxAnte founder and President ...
Breaking Medicine News(10 mins):Health News:1 in 5 U.S. Men Admits to Violence Against Spouse, Partner 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 2Health News:Paediatric Drug Development Market Analysed by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com 3Health News:Patients waiting too long to see doctor? Try 'just-in-time' management methods, researchers urge 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 2Health News:Millennium Health’s RxAnte Subsidiary Announces Leadership Promotions 3
... Rao, an American scientist of Indian origin has been ... a new system which makes use of data for ... is the Senior Director of Engineering Research Development at ... ,Rao is reported to have contributed towards ...
... drinkers go in for wholesome and healthy food, beer drinkers ... also seen among// wine drinkers when compared to beer ... in Copenhagen have found that beer drinkers buy unhealthy food ... prefer wine, according to BBC News. ,Studying ...
... Jefferson and colleagues from Cochrane Collaboration (International private organization ... trials) reviewed data from over 50 clinical trials involving ... researchers found that the old drugs which were used ... some drugs like amantadine and rimantidine which were used ...
... employ people with Asperger's Syndrome, who suffer from difficulties ... total of 50,000 people who suffer from this disorder, ... //People who suffer from the Asperger's Syndrome have difficulty ... though the intelligence of those who suffer from this ...
... Researchers from McMaster University has reported in the Journal ... found that the scientists screened 480 strains of Streptomyces ... all the strains were multi-drug resistance //as they were ... antibiotics. ,The researchers were astonished by ...
... transmission case is due today in Harbin court today. The ... blood collected from an infected couple who sold their blood ... Northeast China. // It was found that 15 people were ... and the other four got infection indirectly from the infected, ...
Cached Medicine News:
125I radioimmunoassay, Simple extraction procedure, Ready-to-use calibrators, Less than 0.1% crossreactivity with DHEA-SO4, 2-hour single incubation, 37C, Calibration Range: 0.5 30 ng/mL...
Inquire...
EL-RF/3 is for measurement of IgM, IgG, IgA RF with high specificity for rheumatoid arthritis....
Rapid latex slide agglutination assay for the qualitative and semi-quantitative determination of Rheumatoid Factors in human serum....
Medicine Products: